Company Encyclopedia
View More
name
Marker Therapeutics
MRKR.US
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc.
1.945 T
MRKR.USMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking158/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-110.67%E
    • Profit Margin-304.54%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-12.99%E
    • Net Profit YoY-47.45%D
    • Total Assets YoY99.21%A
    • Net Assets YoY146.84%A
  • Cash ScoreD
    • Cash Flow Margin-32.84%D
    • OCF YoY-12.99%E
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreA
    • Gearing Ratio15.39%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    High Growth Tech Stocks To Watch In US December 2025

    The US market is experiencing gains due to strong GDP growth and a tech sector rally. Investors are focusing on high-growth tech stocks, assessing their innovation and adaptability. Top companies include Marker Therapeutics, Sanmina, and Palantir Technologies, among others. ADMA Biologics, CarGurus, and Roku are highlighted for their financial performance and strategic initiatives. ADMA shows strong earnings growth, CarGurus has turned profitable, and Roku is enhancing its market position through strategic partnerships.

    Simplywall·
    US
    SANM
    -0.10%
    US
    ADMA
    +0.26%
    US
    MRKR
    +2.96%
    Simplywall·
    US
    SANM
    -0.10%
    US
    ADMA
    +0.26%
    US
    MRKR
    +2.96%

    3 High Growth Tech Stocks To Watch In The US Market

    The U.S. market is experiencing fluctuating indices and AI bubble concerns, with the Dow Jones hitting an all-time high before retreating. High-growth tech stocks to watch include ADMA Biologics, Marker Therapeutics, Palantir Technologies, Workday, Circle Internet Group, Atlassian, RenovoRx, Zscaler, Duos Technologies Group, and Procore Technologies. Notable companies like Annexon, Savara, and MNTN are highlighted for their resilience and strategic growth in the tech sector. These companies are making significant R&D investments and partnerships to navigate market shifts and drive future growth.

    Simplywall·
    US
    MRKR
    +2.96%
    US
    ADMA
    +0.26%
    US
    PLTR
    +0.02%
    Simplywall·
    US
    MRKR
    +2.96%
    US
    ADMA
    +0.26%
    US
    PLTR
    +0.02%

    Canaccord Genuity Keeps Their Buy Rating on Marker Therapeutics (MRKR)

    Canaccord Genuity's John Newman maintains a Buy rating on Marker Therapeutics with a price target of $8.00. Newman, who covers the Healthcare sector, has an average return of -1.4% and a 37.37% success rate. The analyst consensus on Marker Therapeutics is a Moderate Buy with an average price target of $8.00.

    Tip Ranks·
    US
    MRKR
    +2.96%
    Tip Ranks·
    US
    MRKR
    +2.96%

    Marker Therapeutics Showcases MAR-T Cell Therapy Advances and MT-601 Clinical Progress in New Corporate Presentation

    Marker Therapeutics Inc. has released a corporate presentation detailing advancements in its MAR-T cell therapy platform and the clinical progress of its lead product, MT-601. The APOLLO Phase 1 trial for MT-601 shows promising results in lymphoma patients. The company highlights improvements in manufacturing and cell potency, and has secured over $30 million in non-dilutive funding. The presentation underscores Marker Therapeutics' strong intellectual property position.

    Reuters·
    US
    MRKR
    +2.96%
    Reuters·
    US
    MRKR
    +2.96%

    Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma ...

    GlobeNewswire·
    US
    MRKR
    +2.96%
    GlobeNewswire·
    US
    MRKR
    +2.96%
    © 2025 Longbridge｜Disclaimer